Marker Therapeutics Inc (MRKR) Stock Price, Quote & News

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND...

Industry: Biotechnology

Sector: Healthcare

Phone: 713 400 6400

Website: markertherapeutics.com

Address:

2450 Holcombe Blvd, MS: BCM251, Houston, United States

Viperwilder Jun. 16 at 8:44 PM

$MRKR it's reversing

0 · Reply

this_sux Jun. 16 at 8:16 PM

$MRKR Glad I sold most in the 1.80's. Will buy them back under 1.15 if it goes that low again.

0 · Reply

birddogsfly Jun. 16 at 7:03 PM

$MRKR hmmmm

0 · Reply

WhereAmIGoing Jun. 16 at 3:51 PM

$MRKR

0 · Reply

this_sux Jun. 13 at 7:58 PM

$MRKR Painful. I thought maybe we were gaining some traction. How is this in the 1-2 dollar range? Crooked analysts? I hate to keep adding with no real idea as to what is going on.

1 · Reply

WhereAmIGoing Jun. 13 at 2:45 PM

$MRKR

1 · Reply

Viperwilder Jun. 13 at 9:43 AM

$MRKR Today it will crawl back to 1.75

0 · Reply

WhereAmIGoing Jun. 12 at 6:13 PM

$MRKR lost its 1.67 support 😬

1 · Reply

WhereAmIGoing Jun. 12 at 3:31 PM

$MRKR

0 · Reply

WhereAmIGoing Jun. 12 at 2:30 PM

$MRKR not looking good

0 · Reply

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 19, 2025, 8:00 AM EDT - 4 weeks ago

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

Apr 1, 2025, 8:00 AM EDT - 2 months ago

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Mar 31, 2025, 8:45 AM EDT - 2 months ago

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Feb 25, 2025, 7:00 AM EST - 3 months ago

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Dec 19, 2024, 8:06 AM EST - 6 months ago

Marker Therapeutics Announces $16.1 Million Private Placement

Dec 19, 2024, 8:05 AM EST - 6 months ago

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Dec 17, 2024, 7:00 AM EST - 6 months ago

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dec 10, 2024, 8:30 AM EST - 6 months ago

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Nov 26, 2024, 11:00 AM EST - 7 months ago

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Nov 14, 2024, 4:30 PM EST - 7 months ago

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Aug 14, 2024, 4:30 PM EDT - 10 months ago

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 12, 2024, 7:00 AM EDT - 11 months ago

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

May 15, 2024, 4:15 PM EDT - 1 year ago

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Mar 25, 2024, 5:45 PM EDT - 1 year ago

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Mar 22, 2024, 12:30 PM EDT - 1 year ago

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Jan 22, 2024, 7:30 AM EST - 1 year ago

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Jan 8, 2024, 8:24 AM EST - 1 year ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Dec 21, 2023, 11:00 AM EST - 1 year ago

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Nov 9, 2023, 5:00 PM EST - 1 year ago

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Sep 11, 2023, 7:00 AM EDT - 1 year ago

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 9:03 AM EDT - 1 year ago

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Aug 14, 2023, 4:30 PM EDT - 2 years ago

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Jul 10, 2023, 7:00 AM EDT - 2 years ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Jun 26, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Jun 12, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

May 31, 2023, 6:30 AM EDT - 2 years ago

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

May 8, 2023, 7:30 AM EDT - 2 years ago

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

May 1, 2023, 7:30 AM EDT - 2 years ago

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Mar 22, 2023, 8:10 AM EDT - 2 years ago

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Dec 13, 2022, 7:00 AM EST - 2 years ago

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Sep 13, 2022, 7:00 AM EDT - 2 years ago

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Aug 11, 2022, 4:22 PM EDT - 3 years ago

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

$Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma$

Aug 4, 2022, 4:37 PM EDT - 3 years ago

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

May 13, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

May 4, 2022, 10:30 AM EDT - 3 years ago

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting

Mar 17, 2022, 5:45 PM EDT - 3 years ago

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

Mar 7, 2022, 4:05 PM EST - 3 years ago

Marker Therapeutics to Present at Two Upcoming March Investor Conferences

Feb 17, 2022, 1:08 PM EST - 3 years ago

Why Are Marker Therapeutics Shares Trading Lower On Thursday?

Feb 16, 2022, 4:30 PM EST - 3 years ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

Feb 8, 2022, 4:05 PM EST - 3 years ago

Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

Jan 20, 2022, 6:38 AM EST - 3 years ago

Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer

Jan 19, 2022, 4:49 PM EST - 3 years ago

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer

Dec 9, 2021, 7:00 AM EST - 3 years ago

Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors

Nov 18, 2021, 4:05 PM EST - 3 years ago

Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting

Nov 10, 2021, 4:05 PM EST - 3 years ago

Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

Viperwilder Jun. 16 at 8:44 PM

$MRKR it's reversing

0 · Reply

this_sux Jun. 16 at 8:16 PM

$MRKR Glad I sold most in the 1.80's. Will buy them back under 1.15 if it goes that low again.

0 · Reply

birddogsfly Jun. 16 at 7:03 PM

$MRKR hmmmm

0 · Reply

WhereAmIGoing Jun. 16 at 3:51 PM

$MRKR

0 · Reply

this_sux Jun. 13 at 7:58 PM

$MRKR Painful. I thought maybe we were gaining some traction. How is this in the 1-2 dollar range? Crooked analysts? I hate to keep adding with no real idea as to what is going on.

1 · Reply

WhereAmIGoing Jun. 13 at 2:45 PM

$MRKR

1 · Reply

Viperwilder Jun. 13 at 9:43 AM

$MRKR Today it will crawl back to 1.75

0 · Reply

WhereAmIGoing Jun. 12 at 6:13 PM

$MRKR lost its 1.67 support 😬

1 · Reply

WhereAmIGoing Jun. 12 at 3:31 PM

$MRKR

0 · Reply

WhereAmIGoing Jun. 12 at 2:30 PM

$MRKR not looking good

0 · Reply

this_sux Jun. 12 at 12:00 AM

$MRKR Pancreatic cancer trial and AML/MDS trial begin in 2nd half of 2025. maybe something brewing with that? will mark real progress beyond lymphoma and help showcase platform breadth. Anticipated runway into Q1 2026 - hopefully more non-dilutive funding/ or partnership to be announced in the next couple of months. Summer 2025 Apollo readout is the most important potential catalyst. That is what I am waiting for. Maybe breakthrough, fast track, RMAT, or orphan drug status could accelerate development and draw partnership interest. Lots of maybe's.... maybe this recent activity is good or maybe we are just being fucked with again.

1 · Reply

Viperwilder Jun. 11 at 10:31 PM

$MRKR Short term bearish

0 · Reply

Sn1perWolf Jun. 11 at 9:26 PM

$MRKR

0 · Reply

WhereAmIGoing Jun. 11 at 8:11 PM

$MRKR

0 · Reply

WhereAmIGoing Jun. 11 at 6:32 PM

$MRKR hold off on buying before it goes sub 1. Cash burn like crazy Phase 1 trial is as far as they have gotten Terminated contract with manufacturer in March Paying CEO 500K + This company needs a life preserver.

1 · Reply

WhereAmIGoing Jun. 11 at 4:38 PM

$MRKR

1 · Reply

itsMeRich Jun. 11 at 4:37 PM

$MRKR I’m waiting for the news that Mar-t replaces failed Car-t…… then you’ll be buying these shares in the $100’s

0 · Reply

Awesom69Trade Jun. 11 at 4:23 PM

$MRKR come get my shares in double digit, otherwise, I am not selling!

0 · Reply

kshonstocks Jun. 11 at 3:57 PM

$MRKR higher highs off the bottom like patern

0 · Reply

itsMeRich Jun. 11 at 3:54 PM

$MRKR $2 on deck

0 · Reply

Awesom69Trade Jun. 11 at 3:37 PM

$MRKR Over $2 is coming fast then $5

0 · Reply

itsMeRich Jun. 11 at 12:02 PM

$MRKR I’d like to know who purchased those 2 million shares on May 30th……someone knows something.

0 · Reply

Market Cap	18.10M
Revenue (ttm)	6.59M
Net Income (ttm)	-10.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-162.82%
Debt to Equity Ratio	0.00

Volume	184,900
Avg Vol	115,852
Day's Range	N/A - N/A
Shares Out	11.32M
Stochastic %K	13%
Beta	1.44
Analysts	Strong Sell
Price Target	$8.17